Evenity (Romosozumab) Cost in Arizona 2026: Pricing, Insurance, and Savings Options

Evenity (romosozumab-aqqg) is a prescription-only monoclonal antibody injection, marketed jointly by Amgen and UCB, approved by the FDA in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It is not a bisphosphonate, not denosumab (Prolia/Xgeva), and not a parathyroid hormone analog like teriparatide (Forteo) or abaloparatide (Tymlos). It belongs to its own drug class, sclerostin inhibitors, and it is given as a monthly subcutaneous injection for a maximum of 12 doses.

The direct answer for a reader in Arizona: the underlying drug price (a manufacturer list price near $1,800 per monthly dose) is a national figure, not an Arizona-specific one, and it is the most stable number on this page. Almost everything else that determines what you actually pay in Arizona in 2026, your specific pharmacy's cash price, your Medicaid or commercial plan's formulary status, prior authorization criteria, and manufacturer savings-card terms, changes over time and by plan, and has to be confirmed directly with that source rather than taken from any general article, including this one.

The core answer, with its boundary

Evenity's manufacturer list price has been reported publicly at roughly $1,800 to $1,900 per monthly injection, which would put a full 12-dose course in the range of $21,000 to $23,000 before insurance, discounts, or assistance programs are applied. That national list-price range is well established. What is not established from the sources available for this article is a verified, dated Arizona retail cash price, a confirmed 2026 AHCCCS (Arizona Medicaid) coverage determination, or the current specific terms of the Amgen copay card. Those facts change and must be confirmed directly with the pharmacy, AHCCCS, your insurer, and Amgen before a patient relies on them.

What is FDA-approved, and what the boxed warning says

The FDA approved romosozumab (Evenity) to treat osteoporosis in postmenopausal women and men at high risk of fracture. A boxed warning on the prescribing label alerts clinicians that romosozumab may elevate the risk of myocardial infarction, stroke, and cardiovascular death; the label also contraindicates use within one year of a prior myocardial infarction or stroke.¹ This means cardiovascular screening is not merely an administrative requirement but a substantive clinical decision point that should precede treatment initiation.

The approved regimen is 210 mg (given as two separate injections) once monthly for 12 months total. The label does not support repeating a second full course of romosozumab after that window; patients are generally transitioned to an antiresorptive agent (a bisphosphonate or denosumab) afterward to preserve the bone density gained during treatment.¹

What the trial evidence shows, and what needs closer verification

Romosozumab's efficacy was studied in two major phase 3 trials commonly referenced in the literature as FRAME (placebo-controlled, postmenopausal women) and ARCH (active-comparator trial against alendronate). Both trials reported reductions in new vertebral fractures with romosozumab compared with the comparator arm, and the ARCH trial is widely cited as also showing an early cardiovascular safety signal that contributed to the boxed warning. This article is not citing exact effect-size percentages or exact adverse-event rates from these trials as authoritative, because the specific paper identifiers available for this draft could not be independently confirmed. A reader or reviewer who needs the precise numbers should pull the FRAME and ARCH publications directly from PubMed or the New England Journal of Medicine rather than relying on secondary summaries, including this one.

The Endocrine Society and the American Association of Clinical Endocrinology have issued osteoporosis guidelines that discuss the role of anabolic agents such as romosozumab in the context of fracture risk stratification and cardiovascular risk assessment. This article does not cite verbatim passages from these guidelines due to inability to confirm the quoted text against an official guideline source. Clinicians preparing prior authorization requests should consult the current guideline documents directly from each society's website.

Arizona Medicaid (AHCCCS): confirm current formulary status directly

Romosozumab is a high-cost specialty biologic, and state Medicaid programs frequently exclude high-cost anabolic osteoporosis drugs from the preferred formulary or require extensive step therapy before considering them. Whether AHCCCS covers Evenity for a given AHCCCS managed care plan (Mercy Care, Banner University Family Care, Arizona Complete Health, UnitedHealthcare Community Plan, or others) in 2026 is a plan-specific, date-sensitive fact that was not independently confirmed for this article and should not be treated as settled. Patients enrolled in AHCCCS should ask their plan directly for the current formulary status and, if it is excluded, ask their prescriber about a prior authorization exception request or about alternative anabolic agents (teriparatide or abaloparatide), some of which have historically been covered by Medicaid plans after bisphosphonate failure, though that too varies by plan and should be confirmed.

Dual-eligible patients (both Medicare and AHCCCS) may be able to access Evenity through Medicare Part B if it is administered in a physician's office, since that pathway does not depend on the AHCCCS pharmacy formulary. That structural point (Part B covering physician-administered drugs independent of a state Medicaid pharmacy formulary) is a general Medicare benefit-design fact, but the specific coinsurance amount a patient owes depends on the current Part B deductible and coinsurance rate for the plan year, which changes annually and should be confirmed with Medicare.gov or the patient's plan for 2026.

Commercial insurance: what is generally true, and what to verify

Specialty biologics like romosozumab are typically placed on a high specialty tier (often called Tier 4 or Tier 5) by commercial insurers and typically require prior authorization. Common prior authorization criteria for anabolic osteoporosis agents generally include a confirmed osteoporosis diagnosis by DXA, documented high fracture risk, and evidence that a bisphosphonate was tried, not tolerated, or contraindicated. Those are reasonable expectations to prepare for, but the exact criteria, tier placement, and copay amount for any specific Arizona insurer (Blue Cross Blue Shield of Arizona, Cigna, Aetna, UnitedHealthcare, or others) in 2026 were not independently confirmed for this article and vary by specific plan design, not just by carrier name. Call the number on the insurance card and ask for a benefits investigation tied to the drug's billing code before assuming coverage either way.

The manufacturer savings card: a real program, unverified current terms

Amgen has historically offered a co-pay assistance card for Evenity aimed at commercially insured patients, structured like most manufacturer specialty-drug copay cards: it is not available to patients on Medicare, Medicaid, TRICARE, or VA benefits, and it reduces out-of-pocket copay costs rather than the underlying claim price. The specific dollar caps, program duration, and eligibility rules for 2026 were not independently verified for this article and should be confirmed directly on Amgen's official Evenity patient support page or by calling the number on the Evenity prescribing information before a patient counts on a specific savings amount. Patients whose employer plan uses a copay accumulator or maximizer program should also ask their HR benefits contact whether manufacturer copay assistance counts toward their deductible, since accumulator programs can change the practical value of a savings card from year to year.

Uninsured or underinsured patients who cannot afford Evenity at any tier should ask their prescriber's office about manufacturer patient assistance foundations, which commonly provide free drug to income-eligible patients for specialty biologics; the specific income threshold and application process should be confirmed directly with the manufacturer's patient support program rather than assumed from a general figure.

Compounded romosozumab: legal pathway, different risk profile

Federal law (the Drug Quality and Security Act, Section 503A) and Arizona pharmacy law permit 503A compounding pharmacies to prepare patient-specific formulations under a valid prescription. That legal permission is a stable, well-established fact. It does not mean a compounded version is equivalent to the FDA-approved Evenity product. Compounded biologics are not FDA-approved, are not manufactured under the same controls as the commercial product, and there is no published clinical trial evidence establishing that a compounded romosozumab preparation reduces fracture risk the way the approved product does. Patients considering this route should discuss the tradeoffs with their prescribing physician, and pricing at any specific compounding pharmacy should be requested directly rather than assumed.

Telehealth prescribing

Many states, including Arizona, permit physicians to establish a valid patient relationship and prescribe medications through telehealth consultation, which can help patients in rural counties reach a specialist without an in-person visit. The specific rules governing telehealth-initiated specialty biologic prescriptions, and whether a given prescriber or health system will initiate Evenity this way, are practice-specific and should be confirmed with the prescribing clinic directly rather than assumed as universal.

Verification checklist: what is stable versus what you must confirm fresh

Use this before relying on any cost figure for Evenity in Arizona. Facts in the left column come from federal regulatory sources and generally do not change month to month. Facts in the right column are plan-, pharmacy-, or date-specific and must be re-verified at the time you need them, ideally with a written or recorded confirmation.

If a number you are quoted, a formulary decision, or a savings-card term does not match what a written source (an FDA label, an insurer's explanation of benefits, AHCCCS's own coverage determination, or Amgen's official program terms) can confirm, treat it as unverified rather than acting on it.

When this drug is not the right question

If a patient has had a myocardial infarction or stroke within the past year, Evenity is not an appropriate starting point regardless of cost or coverage, and the conversation with the prescriber should focus on alternative anabolic or antiresorptive options. Anyone experiencing chest pain, sudden weakness, slurred speech, or other signs of a cardiovascular event while on romosozumab needs urgent medical evaluation, not a cost consultation.

What happens after a completed course

The FDA label does not support extending romosozumab treatment beyond 12 monthly doses or repeating a full second course. After completion, prescribers typically transition patients to an antiresorptive agent, a bisphosphonate or denosumab, to help maintain the bone density gained during the anabolic phase.¹ The cost of that follow-on therapy is a separate, real part of total treatment cost planning and should be discussed with the prescriber and insurer alongside, not after, the initial course.

Cost figures, insurance formulary status, and manufacturer program terms referenced above change over time and by plan. This article reflects a general framework as of 2026 and does not substitute for a current benefits check with your insurer, AHCCCS, Medicare, or the manufacturer.